

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074270 A3

(51) International Patent Classification⁷: **C07D 309/32**,
405/06, 409/10, 413/10, 407/10, 413/12, 407/06, 405/12,
407/12, 417/10, 409/06, 471/04, 487/04, 285/06, 405/10,
413/06, 417/06, 495/04, 513/04, 405/14, 413/14, 417/12,
473/36, 473/30, A61K 31/351, A61P 31/14

(21) International Application Number:
PCT/IB2004/000493

(22) International Filing Date: 9 February 2004 (09.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(74) Agent: **LUMB, J., Trevor**; Pfizer Inc. c/o Jackie
Lawrence, Eastern Point Road, Mailstop 8260-1615,
Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(30) Priority Data:
60/449,088 21 February 2003 (21.02.2003) US
60/472,355 20 May 2003 (20.05.2003) US

(71) Applicant (for all designated States except US): **PFIZER
INC.** [US/US]; 235 East 42nd Street, New York, NY 10017
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BORCHARDT,
Allen, John** [US/US]; 5419 Via Carancho, San Diego,
CA 92111 (US). **GONZALEZ, Javier** [US/US]; Agouron
Pharmaceuticals, Inc., A Pfizer Company, 10777 Sci-
ence Center Drive, San Diego, CA 92121 (US). **LI, Hui**
[CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Com-
pany, 10777 Science Center Drive, San Diego, CA 92121
(US). **LINTON, Maria, Angelica** [US/US]; Agouron
Pharmaceuticals, Inc., A Pfizer Company, 10777 Science
Center Drive, San Diego, CA 92121 (US). **TATLOCK,
John, Howard** [US/US]; Agouron Pharmaceuticals, Inc.,
A Pfizer Company, 10777 Science Center Drive, San
Diego, CA 92121 (US).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
23 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME



(57) Abstract: The invention relates to compounds of the formula (I) and to phar-
maceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z,
R¹ and R², are as defined herein. The invention also relates to methods of treating Hep-
atitis C virus in mammals by administering the compounds of formula (I), and to phar-
maceutical compositions for treating such disorders, which contain the compounds of
formula (I). The invention also relates to methods of preparing the compounds of for-
mula (I).



WO 2004/074270 A3